Lupus

Hydroxychloroquine dosing higher than 6 mg/kg was associated with a 15-year risk of nearly 22%, while retinopathy risk with shorter duration of use was significantly lower.

Alfredo Aguirre, MD, discusses the latest data regarding lupus this year at the American College of Rheumatology (ACR) Convergence 2022, trends in lupus management, and the importance of remission in lupus.

Self-evidence can help rheumatic autoimmune disease patients gain control of symptoms when the standard of care fails them.

Mymee, a self-advocacy platform, utilizes technological innovation, such as self-tracking, data analytics, and expert health coaching, to improve access and offer hope to these patients by uncovering their unique triggers, managing disease flares, and improving quality of life.

"Discovering your unique triggers can feel frustrating but with the right tools and support, it is possible to find answers," Hinton-Green emphasized. "You don’t have to do it alone."

Enrollment in clinical trials across all disease states, particularly in lupus, continues to be an ongoing challenge.

Dall'Era notes that it is important for rheumatologists to understand that the current endpoints for SLE clinical trials, such as SRI-4 and BICLA, are complex and imperfect. 

Data from a phase 2 trial presented at ACR Convergence 2022 provides clinicians with insight into the effects of deucravacitinib, a TYK2 inhibitor, in patient populations with systemic lupus erythematosus.

A systematic review and meta-analysis presented at ACR Convergence 22 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without systemic lupus erythematosus.

A significantly larger portion of patients in the telitacicept 160 mg achieved SR14 response compared to the placebo group.

Hamilton and his team aim to reduce intensive and often unnecessary screening, including weekly fetal cardiac ultrasounds, via autoantibody identification.

The number of autoantibodies and congenital heart block pregnancies expanded to approximately 30 different autoantibodies to different targets near term.

Investigators believe it is important to understand the patient's perspective regarding vaccine concerns and combining that perspective with stakeholders to prioritize topics for future research.

Bahar Moghaddam, MD, discusses the impact of arthritis worldwide, recent drug approvals, and the importance of early diagnosis and management of rheumatic diseases.

A significantly higher number of patients receiving voclosporin achieved good renal outcome when compared with placebo.

Investigators aimed to assess self-reported changes in physical activity during the COVID-19 pandemic.

"Infections are one of the key determinants of early morbidity and mortality of patients with SLE, strongly linked to disease activity and immunosuppression."

Preventing chronic damage accrual is one of the top treatment targets, as it is linked to increased mortality and decreased quality of life.

A statistically significant elevated risk of SLE was shown among women with low sleep, depression, and bodily pain when compared with those without these concomitant issues.

Drs. Anne E. Winkler and Kristi V. Mizelle share practice pearls to optimize the management of patients of patients diagnosed with lupus.

Experts in rheumatology provide an overview of novel treatment options currently under investigation for the treatment of systemic lupus erythematosus and lupus nephritis.

Kristi V. Mizelle, MD, MPH, FACR comments on long term efficacy data on the use of biologics in lupus, with a focus on preventing organ damage.

"Surveys of patients with SLE and other autoimmune and inflammatory rheumatic diseases have identified vaccine hesitancy in up to 50% of patients, which may be related to concerns about side effects, potential disease flares, or lack of data among patients with SLE.”

Findings demonstrate the utility of machine learning in aiding clinical risk stratification within a complex patient cohort.

The findings of this study of anti-CD19 directed CAR T cell therapy offers new hope for the most severe and refractory cases.